Back to Search
Start Over
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- Source :
- Blood. 126(19)
- Publication Year :
- 2015
-
Abstract
- Programmed cell death ligand 1 (PD-L1) is expressed on both select diffuse large B-cell lymphoma (DLBCL) tumor cells and on tumor-infiltrating nonmalignant cells. The programmed cell death 1 (PD-1)/PD-L1 pathway inhibits host antitumor responses; however, little is known about how this pathway functions in the tumor microenvironment. The aim of this study was to determine the clinicopathological impact of PD-L1(+) DLBCL. We performed PD-L1/PAX5 double immunostaining in 1253 DLBCL biopsy samples and established a new definition of PD-L1(+) DLBCL. We also defined the criteria for microenvironmental PD-L1(+) (mPD-L1(+)) DLBCL (ie, PD-L1(-) DLBCL in which PD-L1(+) nonmalignant cells are abundant in the tumor microenvironment). Of the 273 patients whose clinical information was available, quantitative analysis of PD-1(+) tumor-infiltrating lymphocytes (TILs) was performed. The prevalence rates of PD-L1(+) and mPD-L1(+) DLBCL were 11% and 15.3%, respectively. Both PD-L1(+) and mPD-L1(+) DLBCL were significantly associated with non-germinal center B-cell (GCB) type and Epstein-Barr virus positivity. The number of PD-1(+) TILs was significantly higher in GCB-type tumors and lower in mPD-L1(-) and PD-L1(+) DLBCL. Patients with PD-L1(+) DLBCL had inferior overall survival (OS) compared with that in patients with PD-L1(-) DLBCL (P = .0009). In contrast, there was no significant difference in OS between mPD-L1(+) and mPD-L1(-) DLBCL (P = .31). The expression of PD-L1 maintained prognostic value for OS in multivariate analysis (P = .0323). This is the first report describing the clinicopathological features and outcomes of PD-L1(+) DLBCL. Immunotherapy targeting the PD-1/PD-L1 pathway should be considered in this distinct DLBCL subgroup.
- Subjects :
- Adult
Male
Pathology
medicine.medical_specialty
Adolescent
medicine.medical_treatment
Biopsy
Immunology
Programmed Cell Death 1 Receptor
Biochemistry
B7-H1 Antigen
Disease-Free Survival
immune system diseases
hemic and lymphatic diseases
Tumor Microenvironment
Medicine
Humans
neoplasms
Survival rate
Aged
Retrospective Studies
Aged, 80 and over
Tumor microenvironment
medicine.diagnostic_test
business.industry
Cell Biology
Hematology
Immunotherapy
Middle Aged
medicine.disease
Lymphoma
Neoplasm Proteins
Gene Expression Regulation, Neoplastic
Survival Rate
Apoptosis
Cancer research
PAX5
Female
Lymphoma, Large B-Cell, Diffuse
business
Diffuse large B-cell lymphoma
Subjects
Details
- ISSN :
- 15280020
- Volume :
- 126
- Issue :
- 19
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....46a2921acc03b2265f942a74fc391e5b